117 related articles for article (PubMed ID: 8465418)
1. Cytokine nephropathy during antilymphocyte therapy.
Batiuk TD; Bennett WM; Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):27-30. PubMed ID: 8465418
[No Abstract] [Full Text] [Related]
2. Treatment with poly- and monoclonal antilymphocyte antibodies: assessment of efficacy and safety in transplantation.
Claesson K; Tufveson G; Wahlberg J
Transplant Proc; 1992 Feb; 24(1):314. PubMed ID: 1539293
[No Abstract] [Full Text] [Related]
3. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
4. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
Alamartine E; Bellakoul R; Berthoux F
Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
[No Abstract] [Full Text] [Related]
5. Encephalopathy following the use of OKT3 in renal allograft transplantation.
Shihab FS; Barry JM; Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):31-4. PubMed ID: 8465419
[No Abstract] [Full Text] [Related]
6. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
7. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
8. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
9. Severe allograft dysfunction after OKT3-induced human herpes virus-6 reactivation.
Jacobs U; Ferber J; Klehr HU
Transplant Proc; 1994 Dec; 26(6):3121. PubMed ID: 7998088
[No Abstract] [Full Text] [Related]
10. Evaluation of infections in renal transplant recipients treated with cyclosporine.
Carmellini M; Romagnoli J; Pietrabissa A; Di Stefano R; Oleggini M; Rindi P; Rizzo G; Mosca F
Transplant Proc; 1994 Oct; 26(5):2658-9. PubMed ID: 7940832
[No Abstract] [Full Text] [Related]
11. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).
First MR; Schroeder TJ; Hariharan S
Transplant Proc; 1993 Apr; 25(2 Suppl 1):25-6. PubMed ID: 8465417
[No Abstract] [Full Text] [Related]
12. Acute pancreatitis complicating OKT3 administration for resistant cardiac rejection.
Scheinin S; Radovancevic B; Frazier OH
Transplant Proc; 1993 Jun; 25(3):2368-9. PubMed ID: 8516933
[No Abstract] [Full Text] [Related]
13. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
[No Abstract] [Full Text] [Related]
14. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK
Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
[No Abstract] [Full Text] [Related]
15. Treatment of steroid resistant acute rejection after renal transplantation.
Oh CK; Kim YS; Kim MS; Kim SI; Park K
Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
[No Abstract] [Full Text] [Related]
16. Incidence of de novo malignancies in renal transplant patients after anti-T-lymphocytic therapy.
Kosch M; Könecke J; Hausberg M; Kisters K
Clin Nephrol; 2001 Dec; 56(6):S35-6. PubMed ID: 11770811
[No Abstract] [Full Text] [Related]
17. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
18. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
19. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
20. Cytokine-related encephalopathy induced by OKT3: incidence and predisposing factors.
Shihab F; Barry JM; Bennett WM; Meyer MM; Norman DJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):564-5. PubMed ID: 8438415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
